目的 探討熱淋清顆粒聯(lián)合鹽酸坦索羅辛緩釋膠囊治療慢性前列腺炎的臨床療效。方法 選取2019年10月—2020年1月在天津市寶坻區(qū)人民醫(yī)院就診的102例慢性前列腺炎患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各51例。對(duì)照組口服鹽酸坦索羅辛緩釋膠囊，0.2 mg/次，1次/d。治療組患者在對(duì)照組治療的基礎(chǔ)上溫水沖服熱淋清顆粒，8 g/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，采用前列腺炎癥癥狀評(píng)分（NIH-CPSI）對(duì)患者的病情程度進(jìn)行評(píng)估。使用膀胱測(cè)壓儀檢測(cè)兩組患者治療前后尿動(dòng)力學(xué)的改變。對(duì)比兩組血清γ-干擾素（IFN-γ）、白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，治療組的總有效率為96.08%，對(duì)照組的總有效率為84.31%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的疼痛評(píng)分、排尿癥狀評(píng)分、生活質(zhì)量評(píng)分、NIH-CPSI評(píng)分顯著降低（P<0.05）；治療后，治療組的各評(píng)分比對(duì)照組低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的最大尿流率明顯升高，膀胱頸長度、最大尿道壓力明顯降低（P<0.05）；治療后，治療組的最大尿流率比對(duì)照組高，膀胱頸長度、最大尿道壓力比對(duì)照組低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組IFN-γ、IL-1β、TNF-α水平明顯降低（P<0.05），且治療組IFN-γ、IL-1β、TNF-α水平降低比對(duì)照組更明顯（P<0.05）。結(jié)論 熱淋清顆粒聯(lián)合鹽酸坦索羅辛緩釋膠囊治療慢性前列腺炎的療效確切，可有效控制患者病情，改善尿動(dòng)力學(xué)指標(biāo)，降低炎癥反應(yīng)，安全性良好。

Objective To investigate the clinical efficacy of Relinqing Granules combined with Tamsulosin Hydrochloride Sustained Release Capsules in treatment of chronic prostatitis. Methods Patients (102 cases) with chronic prostatitis in Tianjin Baodi Hospital from October 2019 to January 2020 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Relinqing Granules on the basis of the control group, 8 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the severity of the patients was evaluated by prostatitis symptom score (NIH-CPSI). Bladder manometer was used to detect the changes of urodynamics in the two groups before and after treatment, and the serum levels of IFN-γ, IL-1β, and TNF-α were compared between the two groups. Results After treatment, the total effective rate was 96.08% in the treatment group, and 84.31% in the control group, there was significant difference between two groups (P < 0.05). After treatment, the pain, micturition symptoms, quality of life, and NIH-CPSI score of two groups were significantly decreased (P < 0.05). After treatment, the pain, micturition symptoms, quality of life and NIH-CPSI score in the treatment group were lower than those in the control group (P < 0.05). After treatment, the maximum urinary flow rate were significantly increased, the length of bladder neck and the maximum urethral pressure were significantly decreased (P < 0.05). After treatment, the maximum urinary flow rate in the treatment group was higher than that in the control group, but the length of bladder neck and maximum urethral pressure were lower than those in the control group (P < 0.05). After treatment, the levels of IFN-γ, IL-1β, and TNF-α in two groups were significantly lower (P < 0.05), and the levels of IFN-γ, IL-1β, and TNF-α in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Relinqing Granules combined with Tamsulosin Hydrochloride Sustained Release Capsules is effective in the treatment of chronic prostatitis, which can effectively control the patient's condition, reduce the inflammatory reaction, improve the level of urodynamics, with good safety.

R983

北京市科技計(jì)劃項(xiàng)目（Z171100001017133）